Insuman^®

The remaining presentations of Insuman^® insulin in the UK, listed below, will be discontinued (please refer to expected end of supply dates below). Any Insuman^® currently in the market can continue to be used. This is not due to any safety issues and the DHSC has been informed.

Sanofi is committed to maintaining current supply of our analogue insulins to the UK and Ireland. We continuously reassess our product and device portfolio based on patient need, environmental changes and alternative therapies available. Demand for Insuman® regular human, isophane and isophane pre-mixed insulins has declined significantly in recent years. The discontinuation of the human insulin range, Insuman® is part of our ongoing strategy to reduce manufacturing complexity by removing low-volume products where alternatives are available from other manufacturers. This process allows us to focus our effort and resource on improving capacity for remaining high-volume product lines, including analogue insulins. 

Which presentations are being affected?

1. Insuman^® Basal 100 IU/ml suspension for injection in a cartridge (insulin isophane human) Expected end of supply: End of February 2023
2. Insuman^® Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen (insulin isophane human) Expected end of supply: June 2023
3. Insuman^® Comb 25 100 IU/ml suspension for injection in a cartridge (insulin biphasic isophane human) Expected end of supply: End of February 2023
4. Insuman® Comb 25 SoloStar 100 IU/ml suspension for injection in a pre-filled pen (insulin biphasic isophane human) Expected end of supply: June 2023
5. Insuman® Rapid 100 IU/ml solution for injection in a cartridge (insulin soluble human) Expected end of supply: May 2023

Expected end supply dates are only approximate and supply may be exhausted before/after these dates based on future patient demand.

What does this mean for patients?

It will no longer be an option to start your patients on treatment with Insuman^®. 

If you have patients currently receiving treatment with any of the Insuman^® presentations listed within, they should be moved to a suitable alternative treatment over the coming months under the supervision of their prescribing clinician.

Sanofi remains committed to people living with diabetes in the UK and their clinicians. We continue to act on this commitment through our medicines, services, technologies, and support for the wider community.

If you require any further information in relation to this, please contact:
Medical Information at Sanofi, 410 Thames Valley Park Drive, Reading, RG6 1PT, UK
Tel: +44 (0) 800 035 2525 Email: uk-medicalinformation@sanofi.com